anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Drug Profile

anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Innovative Cellular Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Apoptosis stimulants; Gene expression modulators; Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown B cell lymphoma; Leukaemia

Most Recent Events

  • 06 May 2016 Efficacy data from a Clinical trial in Leukaemia and B-cell lymphoma released by Innovative Cellular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top